Amivantamab for Exon 20-Related NSCLC: Excitement in the Patient Community
We look forward to Dr. Joshua Sabari’s presentation during the oral abstract presentation session “OA04: new Data from Rare EGFR Alterations,” with the welcome CHRYSALIS study results of 8.3 months median progression-free survival and a median overall survival of 22.8 months for this novel EGFR-MET bispecific antibody, amivantamab (JNJ-61186372). Some patients with EGFR exon 20 insertion mutations achieved impressive life extension with good quality of life in the amivantamab post-platinum cohort.1 These data coupled with having worked with Dr. Sabari and members of the amivantamab study team, the Exon 20 Group is excited about the opportunity for appropriate patients to screen for the phase III PAPILLON trial (NCT04538664), which will evaluate amivantamab plus carboplatin-pemetrexed vs. the carboplatin-pemetrexed doublet.
Before a patient begins treatment with amivantamab, the Exon 20 Group’s Angel Buddy Program and our private social media site (admitting only patients receiving amivantamab and their care partners) prepare the patient in advance to understand how infusion-related reactions and other possible side effects are handled. We want to make sure that thoracic oncologists who have had patients with disease progression on poziotinib, mobocertinib, or CLN-081 know that they can request amivantamab for their patients with EGFR mutations who have been pretreated with targeted therapy via Janssen Oncology’s expanded-access program.
References:
- ClinicalTrials.gov. Study of Amivantamab, a Human Bispecific EGFR and cMET Antibody, in Participants with Advanced Non-Small Cell Lung Cancer (CHRYSALIS). https://www.clinicaltrials.gov/ct2/show/NCT02609776?term=amivantamab&co…. Accessed January 25, 2021.
- ClinicalTrials.gov. Pre-Approval Access with Amivantamab (JNJ-61186372) in Participants with Metastatic Non-Small Cell Lung Cancer. https://www.clinicaltrials.gov/ct2/show/NCT04599712?term=amivantamab&co…. Accessed January 25, 2021.
